A detailed history of Bridgeway Capital Management, LLC transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 11,600 shares of KZR stock, worth $76,096. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,600
Previous 108,600 89.32%
Holding current value
$76,096
Previous $65,000 87.69%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.53 - $0.77 $51,410 - $74,690
-97,000 Reduced 89.32%
11,600 $8,000
Q1 2024

May 15, 2024

SELL
$0.8 - $1.05 $40,000 - $52,500
-50,000 Reduced 31.53%
108,600 $97,000
Q4 2023

Feb 14, 2024

SELL
$0.72 - $1.15 $109,080 - $174,225
-151,500 Reduced 48.86%
158,600 $150,000
Q3 2023

Nov 14, 2023

BUY
$1.08 - $2.54 $123,768 - $291,084
114,600 Added 58.62%
310,100 $369,000
Q2 2023

Aug 14, 2023

BUY
$2.31 - $3.06 $451,605 - $598,230
195,500 New
195,500 $478,000
Q1 2022

May 16, 2022

SELL
$12.3 - $18.33 $1.42 Million - $2.12 Million
-115,400 Reduced 80.93%
27,200 $452,000
Q4 2021

Feb 14, 2022

SELL
$7.44 - $16.72 $428,544 - $963,071
-57,600 Reduced 28.77%
142,600 $2.38 Million
Q3 2021

Nov 15, 2021

SELL
$4.85 - $9.73 $121,249 - $243,250
-25,000 Reduced 11.1%
200,200 $1.73 Million
Q2 2021

Aug 16, 2021

SELL
$4.93 - $6.46 $49,300 - $64,600
-10,000 Reduced 4.25%
225,200 $1.22 Million
Q1 2021

May 17, 2021

BUY
$5.24 - $6.99 $1.23 Million - $1.64 Million
235,200 New
235,200 $1.4 Million
Q2 2020

Aug 14, 2020

SELL
$3.6 - $7.75 $179,895 - $387,275
-49,971 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$2.77 - $5.75 $78,108 - $162,138
-28,198 Reduced 36.07%
49,971 $218,000
Q4 2019

Feb 14, 2020

BUY
$2.5 - $4.26 $90,927 - $154,940
36,371 Added 87.02%
78,169 $313,000
Q3 2019

Nov 14, 2019

BUY
$3.0 - $7.58 $125,394 - $316,828
41,798 New
41,798 $137,000

Others Institutions Holding KZR

About Kezar Life Sciences, Inc.


  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $449M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.